within Pharmacolibrary.Drugs.N_NervousSystem.N01A_AnestheticsGeneral.N01AX14_Esketamine;

model Esketamine_1
  extends Pharmacolibrary.Drugs.ATC.N.N01AX14_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N01AX14_1</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Esketamine is the S-enantiomer of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is used as an anesthetic agent and, more recently, as an antidepressant for treatment-resistant depression. Esketamine nasal spray is approved for use in adults with treatment-resistant depression in combination with another oral antidepressant.</p><h4>Pharmacokinetics</h4><p>Intranasal administration in adults with treatment-resistant depression.</p><h4>References</h4><ol><li><p>Kurosawa, K, et al., &amp; Pérez-Ruixo, C (2023). Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study. <i>Clinical pharmacology in drug development</i> 12(4) 397–406. DOI:<a href=\"https://doi.org/10.1002/cpdd.1214\">10.1002/cpdd.1214</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36560916/\">https://pubmed.ncbi.nlm.nih.gov/36560916</a></p></li><li><p>Sanders, B, &amp; Brula, AQ (2021). Intranasal esketamine: From origins to future implications in treatment-resistant depression. <i>Journal of psychiatric research</i> 137 29–35. DOI:<a href=\"https://doi.org/10.1016/j.jpsychires.2021.02.020\">10.1016/j.jpsychires.2021.02.020</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33647726/\">https://pubmed.ncbi.nlm.nih.gov/33647726</a></p></li><li><p>Zannikos, P, et al., &amp; Singh, J (2023). Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment. <i>Clinical pharmacokinetics</i> 62(9) 1315–1328. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01273-z\">10.1007/s40262-023-01273-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37402024/\">https://pubmed.ncbi.nlm.nih.gov/37402024</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Esketamine_1;
